216 related articles for article (PubMed ID: 9331009)
1. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension.
Zanchetti A; Omboni S; Di Biagio C
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S57-9. PubMed ID: 9331009
[No Abstract] [Full Text] [Related]
2. Antihypertensive effects of candesartan cilexetil, enalapril and placebo.
Franke H
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S61-2. PubMed ID: 9331010
[No Abstract] [Full Text] [Related]
3. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
Malmqvist K; Kahan T; Dahl M
Am J Hypertens; 2000 May; 13(5 Pt 1):504-11. PubMed ID: 10826401
[TBL] [Abstract][Full Text] [Related]
4. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
Baumgart P; Reismann J; Pohlmeyer H; Düsing R
Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension.
Andersson OK; Neldam S
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S63-4. PubMed ID: 9331011
[No Abstract] [Full Text] [Related]
6. Role of the renin-angiotensin system in hypertension in the elderly.
Nagano M; Higaki J; Mikami H; Ogihara T
Blood Press Suppl; 1994; 5():130-3. PubMed ID: 7889195
[TBL] [Abstract][Full Text] [Related]
7. Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Multicentre Cough Study Group.
Tanser PH; Campbell LM; Carranza J; Karrash J; Toutouzas P; Watts R
Am J Hypertens; 2000 Feb; 13(2):214-8. PubMed ID: 10701823
[TBL] [Abstract][Full Text] [Related]
8. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension.
Heuer HJ; Schöndorfer G; Högemann AM
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S55-6. PubMed ID: 9331008
[No Abstract] [Full Text] [Related]
9. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension.
Sever P; Holzgreve H
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S69-73. PubMed ID: 9331014
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.
Ogihara T; Arakawa K
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S27-31; discussion S33-4. PubMed ID: 10076918
[TBL] [Abstract][Full Text] [Related]
11. Comparison of candesartan versus enalapril in essential hypertension. Italian Candesartan Study Group.
Zanchetti A; Omboni S
Am J Hypertens; 2001 Feb; 14(2):129-34. PubMed ID: 11243303
[TBL] [Abstract][Full Text] [Related]
12. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
Sever P
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of candesartan cilexetil in special patient groups.
Trenkwalder P
Blood Press Suppl; 2000; 1():27-30. PubMed ID: 11059633
[TBL] [Abstract][Full Text] [Related]
14. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.
Himmelmann A; Keinänen-Kiukaanniemi S; Wester A; Redón J; Asmar R; Hedner T;
Blood Press; 2001; 10(1):43-51. PubMed ID: 11332334
[TBL] [Abstract][Full Text] [Related]
15. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
Rosei EA; Rizzoni D; Muiesan ML; Sleiman I; Salvetti M; Monteduro C; Porteri E;
J Hypertens; 2005 Feb; 23(2):435-44. PubMed ID: 15662233
[TBL] [Abstract][Full Text] [Related]
16. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM
Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
[TBL] [Abstract][Full Text] [Related]
17. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
Sever PS
Blood Press Suppl; 2000; 1():19-22. PubMed ID: 11059631
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
McInnes GT; O'Kane KP; Jonker J; Roth J
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S75-80. PubMed ID: 9331015
[TBL] [Abstract][Full Text] [Related]
19. Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension.
Philipp T; Letzel H; Arens HJ
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S67-8. PubMed ID: 9331013
[No Abstract] [Full Text] [Related]
20. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
Sever PS
J Hypertens Suppl; 1997 Dec; 15(6):S9-12. PubMed ID: 9493121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
